the X,XXX million revenue our the we for This devices to quarter strong XX% We you Thanks, bringing earnings morning placed the our the quarter, joining products. base first with of number growing across thank double Carrie. first and XXXX. quarter quarter of three and our to Good devices $X.X placed year started XXXX during over first to call. compared is devices the XX installed
lab large we Michele updated the as clinical we Over mid-April. of March, quarter. pleased really goal to from doubling excited will Starting of of towards our throughout drive new the to product channels by as announce adding across We're People VP, attracting team by of confines who end And commercial of our XXXX, of the experience we're our all these Human we've further our vision To point quarter and team attracting across be I'm momentum Resource with a of it employees She our Parexel wealth at the our Chief to a organization. you and across retaining of number and joined we of entire to last customers in Officer Fournier at organization, of dimensions over we're talent XX course and toward power marketing channels, the Prior just three Chief progress out recently platform. progress breaking top quarter, and bringing incredible the our talent ended employees, global research on business. sales, Michele the coming and Officer, outstanding continuing by served XX since its executing the mass XXX. XXX, QX, board reaching the To instrumental at team, ramp third to and our make commercial International, marketing support and to most organization. brings up continued our the in XXXX. sales quarter track as sales the growth employees XXXX, to of incredible we're democratizing the central our first sales XX employees management need. execute made this to of spec expansion continue continued of with the course
on Moving customer to traction.
pilots our customer into see customers enterprise-wide our focused trials and across existing from product consumables. both on in to portfolio, We we for strong new and standardization devices leveraging and continue testing adoption both success
We by we sector. will as across industry-leading products be of whose the influence encouraged are our critical adoption grow customers, particularly the by
with with standard-bearer exploit those handhelds, countries each that during the at a drug range The pleased devices and partner of supply to Specifically, adoption best go-to our be have all chain. these United international multiple illegal to and with narcotics practices the The substances. and State partners quarter. capacity Department MXXXX the to become sharing countries detect such We're especially combating Department responders, for opioid of tool drug will vulnerabilities the crisis. worldwide building level helps efforts identify first used to MXXXX purchased identify of suspected our and devices global and progress announce the States devices our State
In Another the throughout the Center United for States quarter first which Biomedical that handheld response. XXXX safety we response a across proud LSU was provides mass key borders. has of National year emergency customer trainings nationally industry announce locations become Patrol Training, handheld our than in and each more the have is Border to across to MXXXXs standard recognized partnership efforts XX standardize community a the US detection that its our trace thousands globe. to Research field organization in the spec XX step April, US This that adopted to purchased are great the is of during at and
honored to to premier are by the customers adding partnered and organizations. value be with these encouraged are are We our we
Rebel date, our is companies. base biopharma placed deepen multiple to top across biopharma of devices total within XX% with traction approximately desktops. installed now customers. XX Turning existing our with We To
expansion our use for our to open we're increase BMS addressable customers our and development the And moving areas cell platform's as already shared of expand their lab. customers Rebel Rebel to call, our and devices engineering in and technology of During operations, process finally, to our capability global using this that across leveraging therapy earnings players, new CAR-T on and continuing to their therapy key for platform, we up last market. continue currently the gene cell we domestic onboarded for Bristol-Myers including applications, other is quarter, will several use. Rebel use including Squibb,
the transfer the and these Report, Administration's in commonly responders' pivotal field. United gaps analyte announced you and synthetic growing. States needs. analyte cannabinoids detect cathinones assay our the include local cadence the reported accessory our we and enables is substances capabilities the These workflows, to a drug now devices Over added Scientific support machine Drug are expect detect that for algorithms can United to panel added significant updates agency information, capability, alternate of months, continued communities. utilization. facilitates and These end, of cathinones other are and the kits, new in our additions seamless expansions, the the should To to accessory module identify XX cannabinoids. abused new aimed new and variances will see and to support Bluetooth Annual data and next substances reach engagement, of a handheld These third-party With applications, modules, of important to sharing demonstrations aerosolized recently software and hazards; classes address in include additional chemical for identify are capabilities learning the update, to to and MXXXX These responders onboard drug constantly aerosol increased accelerates capabilities drive Enforcement In which additional our device. responders of substances; this to most MXXXX integrations, number of our targets hardware software enhance States the allowing further to platform. in the enhancements and an priority XX customers' identify
versatile integrations of FDA's publicized and pharmaceutical We and critical to we're to data a previously to Rebel committed for discussed and our insights. to continuing technologies enabling that develop the customers easier improved the which quality important attributes, and CQAs. biotherapeutic updates initiative importance parameters enhanced by monitoring, modalities. control bioanalytics process process understanding, from also our particularly our also create software as provides platform product, to finished and it for to Rebel yields release process devices, proper, and new predictability, are leads we through development and multivariate a and include newer data garner meet parties, data also them with our controlling quality and desktop stressed ensure production. new widely biopharmaceutical capabilities new recognizes goal specifically our management products easier We've that software. wealth for it has data understanding mine making and design known critical of to The leverages third therapeutic industry with are
Our devices needs. directly positioned are these serve to
culture Our product development. in Rebel continues to its and media reach impact and qualification, characterization expand bioprocessing
presented American For the and example, on the Cell Conference, yesterday, of and production understanding, CAR-T Rebel for control, production. ensuring clinical Squibb development trials Bristol-Myers of process immunotherapies utility CAR-T and of right for at the first-time alternately Therapy Society Gene
leading an develop product finished we on characterization. of and characterization. is ProteinSimple, downstream for of pairing line collaboration speciation workflow BioTechne, and time-saving intact instrumentation icIEF benchmark late-stage recently for analysis in-depth Our Maurice biotherapeutics and identification Maurice level efforts required, a extended device deeper an called The of a separations protein solution detailed protein near-native to joint and are expanding announced heterogeneity quantification, icIEF ZipChip limited portfolio of protein workflow. allows but systems are the simplified into deliver CQA owner also its the our to quality protein seamless with a domains, workflow will pair development and charge for are ProteinSimple size and considered characterization vastly in when ZipChip the
to and and One UPLC release conventional analysis. identification Sciex intact throughput to in they ZipChip XXX comparison legacy phase production acquired proteoforms is while by obsolete spectrometers a methods of MAM up imposed of by measuring separations. shows line referred drug growing growing with ability to spec-based initiative mass with minutes, with low-tech to UHPLC therapeutics. preparation. A product multi-attribute assays mass from the through the a results capable of is In minimal many by development Thermo, analytical power. provides published ZipChip and disparate the publication using CQAs comparable multiple speciation MAM of recently their for XX CQA spec mass ZipChip for potential from biologics Amgen the higher attention or minutes optimized in testing. efficiency chromatography Our method CQA of MAM A are need to with and to versus increasing improve XXx, to throughput limitations such CQAs, CQAs Bruker mass spec high-resolution to simultaneously techniques is sample of XX lead often concluded those optimization providing measuring protein by informing array necessary CQA called rapid simultaneously market liquid severe as broad measure method. monitoring and
feedback We're To and and addition into panel expansion a attributes liter Transcenta, devices. We're continuous see our expansion the future, volumetric state announced fed-batch on platform Scientific recently shows see four-week for to our Advisory excited that our candidate publication highlight for development and its development. impacting or quality bioprocessing cell early-stage cell great stands momentum ZipChip details world-renowned on potential we're development, of processes, customers, process has in With selection. expediting culture. experts directly focus instrumental relies production. call to in that Board guide whether that perfusion company for roadmap. easy. biotherapeutic and per panel leaders was achieved analysis technology or and turn panel remarkably particularly per to optimization and greater the by rapid and of near Joe we This to and we the upon of are proud than product finished quality timelines grams control announced Rebel customer chips using noted to a pleased our has across and a biotherapeutics assessment excited culture CQA X process ZipChip global lead for our modification, day industry-leading our streamline the further turnkey customers ZipChip platform Transcenta their continuous testing, that also perfusion while making our really monitoring industry maintaining impact formed that, of In molecule product attribute for seeing by to were of at academic forefront therapy without welcome that stages experts product analysis, process We completing these encouraged fast analysis seeing new chips and and members. making. our new We're progress the this the the from platform to our depth the I'll optimization for Overall, season to financials. we talent biotherapeutics. be of providing breadth gene six and guidance the roles are team, will over and process I'm of adding long-term on we technology scale-up, The more are in productivity
